Nuclear Receptor Function in Hepatic Pathology

$135,000U19FY2008DKNIH

Baylor College Of Medicine, Houston TX

Investigators

Linked publications & trials

Paper 28378930 Paper 27432117 Paper 26611104 Paper 26544941 Paper 26487511 Paper 26356605 Paper 26267291 Paper 26098212 Paper 26076474 Paper 25951943 Paper 25865501 Paper 25830341 Paper 24905738 Paper 24878540 Paper 24703703 Paper 24529706 Paper 24268772 Paper 24162845 Paper 23978678 Paper 23933984 Paper 23933983 Paper 23927929 Paper 23757177 Paper 23728303 Paper 23725765 Paper 23567971 Paper 23553833 Paper 23504956 Paper 23315938 Paper 23300926 Paper 23257920 Paper 23201680 Paper 23159735 Paper 23038264 Paper 22999881 Paper 22996661 Paper 22962329 Paper 22958921 Paper 22912762 Paper 22786849 Paper 22745194 Paper 22734043 Paper 22700587 Paper 22684107 Paper 22669823 Paper 22645148 Paper 22560224 Paper 22522926 Paper 22505454 Paper 22492355 Paper 22484817 Paper 22465074 Paper 22460952 Paper 22406377 Paper 22371499 Paper 22315431 Paper 22304921 Paper 22219718 Paper 22207717 Paper 22170608 Paper 22170062 Paper 22135047 Paper 22106289 Paper 22078881 Paper 22001906 Paper 21940749 Paper 21873211 Paper 21859476 Paper 21801835 Paper 21778422 Paper 21749634 Paper 21641554 Paper 21620140 Paper 21605560 Paper 21565617 Paper 21498392 Paper 21472695 Paper 21436455 Paper 21372815 Paper 21356518 Paper 21300871 Paper 21292830 Paper 21289626 Paper 21284836 Paper 21273443 Paper 21257780 Paper 21195347 Paper 21179495 Paper 21141906 Paper 21123945 Paper 21123943 Paper 21109193 Paper 21106671 Paper 21029773 Paper 20956526 Paper 20887900 Paper 20850017 Paper 20813267 Paper 20714342 Paper 20685849

Abstract

Two specific areas with particular relevance to this project arescreening for the impact of metabolic signals and metabolic disease on hepatic expression of microRNAs, and the role of NRs and their targets in adverse drug reactions. This project is based on two general hypotheses: 1) Micro RNA expression is altered in response to nuclear receptor activation and other metabolic signals in the liver, allowing non-proliferative hepatocytes to alter their function over time. 2) The induction of hepatotoxicity in adverse drug reactions is associated with large scale alterations in expression of NRs, their coregulators and downstream metabolic targets, and distinct classes of hepatotoxic agents elicit distinct responses. We will test both hypotheses by leveraging the ongoing high throughput QPCR screening technologies developed by this Strand in the initial Phase of the NURSA project.

View original record on NIH RePORTER →